<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898400</url>
  </required_header>
  <id_info>
    <org_study_id>21-000959</org_study_id>
    <nct_id>NCT04898400</nct_id>
  </id_info>
  <brief_title>Eosinophils in Human Adipose Tissue</brief_title>
  <official_title>Role of Eosinophils in Human Adipose Tissue Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the interactions between the innate immune&#xD;
      system, in particular eosinophils (EOS), and adipose tissue (AT) in human health and in&#xD;
      disease states such as obesity and insulin resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight loss</measure>
    <time_frame>at 30 days post-intervention</time_frame>
    <description>total body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>weight loss</measure>
    <time_frame>at 60 days post-intervention</time_frame>
    <description>total body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>weight loss</measure>
    <time_frame>at 90 days post-intervention</time_frame>
    <description>total body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fat mass</measure>
    <time_frame>at 30 days post-intervention</time_frame>
    <description>% fat mass will be estimated by bioimpedence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fat mass</measure>
    <time_frame>at 60 days post-intervention</time_frame>
    <description>% fat mass will be estimated by bioimpedence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fat mass</measure>
    <time_frame>at 90 days post-intervention</time_frame>
    <description>% fat mass will be estimated by bioimpedence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AT-EOS content</measure>
    <time_frame>at baseline</time_frame>
    <description>subcutaneous fat biopsy will be processed to extract stromal vascular fraction (SVF) which will contain eosinophils. The SVF will be run trough flow cytometry to get an estimated count to be reported as a ratio over the total number of cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AT-EOS content</measure>
    <time_frame>at 90 days post-intervention</time_frame>
    <description>subcutaneous fat biopsy will be processed to extract stromal vascular fraction (SVF) which will contain eosinophils. The SVF will be run trough flow cytometry to get an estimated count to be reported as a ratio over the total number of cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>at baseline and 90 days post-intervention</time_frame>
    <description>mixed meal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>at 30 days post-intervention</time_frame>
    <description>Plasma will be isolated during fasting condition. MCP-1, TNFa, IL-4, IL-13, Leptin, adiponectin will be assessed via Multiplex ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>at 60 days post-intervention</time_frame>
    <description>Plasma will be isolated during fasting condition. MCP-1, TNFa, IL-4, IL-13, Leptin, adiponectin will be assessed via Multiplex ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>at 90 days post-intervention</time_frame>
    <description>Plasma will be isolated during fasting condition. MCP-1, TNFa, IL-4, IL-13, Leptin, adiponectin will be assessed via Multiplex ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue inflammation</measure>
    <time_frame>at baseline</time_frame>
    <description>subcutaneous fat biopsy will be processed to obtain mRNA. mRNA levels for MCP-1, TNFa, IL-4, IL-13, Leptin, adiponectin gene will be assessed via qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue inflammation</measure>
    <time_frame>at 90 days post-intervention</time_frame>
    <description>subcutaneous fat biopsy will be processed to obtain mRNA. mRNA levels for MCP-1, TNFa, IL-4, IL-13, Leptin, adiponectin gene will be assessed via qPCR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Subjects with Obesity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be recruited to undergo endoscopic sleeve gastroplasty. The subjects will be studied at baseline, 30, 60, 90 days after procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopy sleeve gastroplasty</intervention_name>
    <description>endoscopic procedure for weight loss</description>
    <arm_group_label>Subjects with Obesity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obesity (BMI&gt;30 kg/m2).&#xD;
&#xD;
          -  Evidence of insulin resistance as defined by hemoglobin A1c &gt; 5.7%.&#xD;
&#xD;
          -  Mayo Clinic patients evaluated by Dr. Rahul Pannala.&#xD;
&#xD;
          -  Pursue an endoscopic gastroplasty at Mayo Clinic Arizona in the Gastroenterology&#xD;
             department.&#xD;
&#xD;
          -  Equal distribution of gender.&#xD;
&#xD;
          -  18 yo older of age.&#xD;
&#xD;
          -  BMI&gt;30 kg/m2.&#xD;
&#xD;
          -  Nonsmoker.&#xD;
&#xD;
          -  Taking no medication affecting glucose or lipid metabolism.&#xD;
&#xD;
          -  No more than 5% change in body weight in the previous 6 months.&#xD;
&#xD;
          -  Mostly sedentary (engaging in strenuous exercise (&gt; 70% max HR) less than 3 times a&#xD;
             week).&#xD;
&#xD;
          -  Not be receiving corticosteroid therapy.&#xD;
&#xD;
          -  Have no history of asthma, COPD or atopic syndrome, or autoimmune disease (Ulcerative&#xD;
             colitis, Chron's disease, eosinophilic esophagitis, any rheumatologic disease such as&#xD;
             lupus, rheumatoid arthritis, Sjogren syndrome).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;17 years of age.&#xD;
&#xD;
          -  BMI &lt;30 kg/m2.&#xD;
&#xD;
          -  Smoker.&#xD;
&#xD;
          -  Taking medication affecting glucose or lipid metabolism.&#xD;
&#xD;
          -  Greater than 5% change in body weight within the previous six months.&#xD;
&#xD;
          -  Engage in strenuous exercise (&gt;70% max HR) less than 3 times a week.&#xD;
&#xD;
          -  Receiving corticosteroid therapy.&#xD;
&#xD;
          -  Have a history of asthma.&#xD;
&#xD;
          -  History of COPD or atopic syndrome.&#xD;
&#xD;
          -  History of autoimmune disease (Ulcerative colitis, Chron's disease, eosinophilic&#xD;
             esophagitis, any rheumatologic disease such as lupus, rheumatoid arthritis, Sjogren&#xD;
             syndrome).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Anna O. De Filippis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 16, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Elena Anna (Eleanna) De Filippis, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

